Augmedix Delivers Continued Sales Momentum; Reports First Quarter 2023 Financial Results
SAN FRANCISCO, May 12, 2023 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical...
Day: May 12, 2023
Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment, with...
Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference
CUPERTINO, Calif., May 12, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...
AirSculpt® Technologies, Inc. Introduces Its Next Generation Body Contouring Experience in London
Elite Body Sculpture London 1 51 Harley Exterior Elite Body Sculpture London 2 51 Harley InteriorMIAMI BEACH, Fla., May 12,...
Mendus AB: Report from the Annual General Meeting of Mendus AB (publ) on 12 May 2023
At the annual general meeting (the “AGM”) of Mendus AB (publ), reg. no. 556629-1786, (the “Company”), on 12 May 2023...
Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting
Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting HARMONIE Phase 3b data reinforce nirsevimab’s...
HUTCHMED Announces Board of Directors and Board Committee Membership
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or...
Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2023
Tokyo, Japan and Cambridge, UK, 12 May 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on...
Mendus AB: Mendus AB (publ) Interim Report January – March 2023
In the first quarter of 2023, Mendus continued on the path set out by the key progress realized at the...
Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors
NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology...